These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 10081033)

  • 1. [Factors in the progression of renal insufficiency during the 2 years preceding the use of dialysis].
    Kacso I; Gherman M; Mazouz H; Ghazali A; el Esper N; Morinière P; Makdassi R; Hardy P; Westeel PF; Achard JM; Pruna A; Fournier A
    Nephrologie; 1999; 20(1):19-28. PubMed ID: 10081033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors of renal failure progression two years prior to dialysis.
    Mazouz H; Kacso I; Ghazali A; El Esper N; Moriniere P; Makdassi R; Hardy P; Westeel PF; Achard JM; Pruna A; Fournier A
    Clin Nephrol; 1999 Jun; 51(6):355-66. PubMed ID: 10404696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progression rate to end-stage renal failure in non-diabetic kidney diseases: a multivariate analysis of determinant factors.
    Jungers P; Hannedouche T; Itakura Y; Albouze G; Descamps-Latscha B; Man NK
    Nephrol Dial Transplant; 1995; 10(8):1353-60. PubMed ID: 8538926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decline of renal function is associated with proteinuria and systolic blood pressure in the morning in diabetic nephropathy.
    Suzuki H; Kanno Y; Nakamoto H; Okada H; Sugahara S
    Clin Exp Hypertens; 2005; 27(2-3):129-38. PubMed ID: 15835375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of hypertension in chronic kidney disease.
    Toto RD
    Semin Nephrol; 2005 Nov; 25(6):435-9. PubMed ID: 16298269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study.
    Iino Y; Hayashi M; Kawamura T; Shiigai T; Tomino Y; Yamada K; Kitajima T; Ideura T; Koyama A; Sugisaki T; Suzuki H; Umemura S; Kawaguchi Y; Uchida S; Kuwahara M; Yamazaki T;
    Clin Exp Nephrol; 2003 Sep; 7(3):221-30. PubMed ID: 14586719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteinuria in mild to moderate hypertension: results of the VA cooperative study of six antihypertensive agents and placebo. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.
    Preston RA; Materson BJ; Reda DJ; Hamburger RJ; Williams DW; Smith MH
    Clin Nephrol; 1997 May; 47(5):310-5. PubMed ID: 9181278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors affecting progression in advanced chronic renal failure.
    Hannedouche T; Chauveau P; Kalou F; Albouze G; Lacour B; Jungers P
    Clin Nephrol; 1993 Jun; 39(6):312-20. PubMed ID: 8334758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Differences between the glomerular filtration rate estimated by the MDRD equation and the measurement of creatinine and urea clearance in unselected patients with terminal renal insufficiency].
    Caravaca F; Arrobas M; Luna E; Naranjo M; Pizarro JL; Sánchez-Casado E
    Nefrologia; 2002; 22(5):432-7. PubMed ID: 12497744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hypertension in hemodialysis patients in Andalucia].
    García Cortés MJ; Ceballos M;
    Nefrologia; 2004; 24(2):149-57. PubMed ID: 15219090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic effects of keto acid--amino acid supplementation in patients with chronic renal insufficiency receiving a low-protein diet and recombinant human erythropoietin--a randomized controlled trial.
    Teplan V; Schück O; Votruba M; Poledne R; Kazdová L; Skibová J; Malý J
    Wien Klin Wochenschr; 2001 Sep; 113(17-18):661-9. PubMed ID: 11603100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of rates and risk factors for developing chronic renal insufficiency, proteinuria and metabolic acidosis after radical or partial nephrectomy.
    Malcolm JB; Bagrodia A; Derweesh IH; Mehrazin R; Diblasio CJ; Wake RW; Wan JY; Patterson AL
    BJU Int; 2009 Aug; 104(4):476-81. PubMed ID: 19220252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chronic kidney disease in the source documentation of the outpatient clinic Department of Nephrology. Part I. Causes of renal failure and characteristics of the studied population].
    Kopeć J; Januszek R; Wieczorek-Surdacka E; Sułowicz W
    Przegl Lek; 2009; 66(12):1003-10. PubMed ID: 20514896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The optimization of the treatment and timing of the intervention by a nephrologist in pre-dialytic chronic renal insufficiency].
    Sirignano C; D'Urso P; Di Iorio BR;
    G Ital Nefrol; 2003; 20(2):133-8. PubMed ID: 12746798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of obesity on progression of non-diabetic chronic kidney disease: a retrospective cohort study.
    Othman M; Kawar B; El Nahas AM
    Nephron Clin Pract; 2009; 113(1):c16-23. PubMed ID: 19590231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of dialysis sodium gradient on intradialytic hypertension: an observational study.
    Movilli E; Camerini C; Gaggia P; Zubani R; Feller P; Poiatti P; Pola A; Carli O; Valzorio B; Cancarini G
    Am J Nephrol; 2013; 38(5):413-9. PubMed ID: 24216674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Slow progression of chronic kidney disease and what it is associated with.
    Eftimovska N; Stojceva-Taneva O; Polenakovic M
    Prilozi; 2008 Jul; 29(1):153-65. PubMed ID: 18709007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term renal function in primary hypertension. An epidemiological and pathophysiological study.
    Siewert-Delle A
    Scand J Urol Nephrol Suppl; 1999; 199():1-36. PubMed ID: 10349677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
    Ruilope LM; Aldigier JC; Ponticelli C; Oddou-Stock P; Botteri F; Mann JF
    J Hypertens; 2000 Jan; 18(1):89-95. PubMed ID: 10678548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Failure of dietary protein and phosphate restriction to retard the rate of progression of chronic renal failure: a prospective, randomized, controlled trial.
    Williams PS; Stevens ME; Fass G; Irons L; Bone JM
    Q J Med; 1991 Oct; 81(294):837-55. PubMed ID: 1801057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.